• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian Journal of Neurological Sciences: le Journal Canadien des Sciences Neurologiques >Anti-JC Virus Antibody Prevalence in Canadian MS Patients
【24h】

Anti-JC Virus Antibody Prevalence in Canadian MS Patients

机译：加拿大MS患者的抗JC病毒抗体患病率

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Anti John Cunningham (JCV) antibodies have been detected in approximately 50% to 60% of multiple sclerosis (MS) patients. Age, sex, and geographic location have been associated with seroprevalence differences. We describe anti-JCV antibody prevalence in the Canadian cohort of patients enrolled in the JCV Epidemiology in MS study. Methods: This cross-sectional multicenter study evaluated the effects of demographic and disease characteristics on anti-JCV antibody seroprevalence in MS patients irrespective of disease type and treatment. A single blood sample was collected for analysis of anti-JCV antibodies using a two-step enzyme-linked immunosorbent assay (ELISA). Chi-square and logistic regression tests were used to determine significance. Results: A total of 4198 Canadian MS patients participated in the study: the overall anti-JCV antibody prevalence was 56.3% (95% confidence interval: 54.8% to 57.8%). Seroprevalence was significantly associated with age (increasing from 45% in young to 61% in those >60 years), sex, and region (p < 0.0001 for age and sex; p = 0.005 for region). No significant differences in anti-JCV antibody prevalence were associated with race, MS disease type and duration, or number and duration of treatments. Immunosuppressant use was associated with a higher seroprevalence rate (63.4%) compared with no immunosuppressant use (55.9%; p = 0.040). Conclusions: Canadian MS patients had an overall anti-JCV antibody seroprevalence that was consistent with previous studies using the two-step ELISA. Significant associations of anti-JCV antibody positivity were found with age, sex, region, and immunosuppressant therapy, whereas seroprevalence was not associated with race, MS type, MS duration, or number or duration of MS treatments.
机译：背景：已在约50％至60％的多发性硬化症（MS）患者中检测到抗John Cunningham（JCV）抗体。年龄，性别和地理位置与血清阳性率差异有关。我们描述了在MS研究中参加JCV流行病学的加拿大人群中的抗JCV抗体患病率。方法：这项横断面的多中心研究评估了人口统计学和疾病特征对MS患者抗JCV抗体血清阳性率的影响，而与疾病类型和治疗无关。使用两步酶联免疫吸附测定（ELISA）收集单份血液样品以分析抗JCV抗体。卡方检验和逻辑回归检验用于确定显着性。结果：总共4198名加拿大MS患者参加了该研究：总体抗JCV抗体患病率为56.3％（95％置信区间：54.8％至57.8％）。血清阳性率与年龄（年龄从60％的年轻人从45％增加到60岁以上的61％），性别和地区密切相关（年龄和性别p <0.0001;地区p = 0.005）。抗JCV抗体患病率与种族，MS疾病类型和持续时间或治疗次数和持续时间无显着差异。与不使用免疫抑制剂（55.9％; p = 0.040）相比，使用免疫抑制剂的血清阳性率更高（63.4％）。结论：加拿大MS患者的总体抗JCV抗体血清阳性率与先前使用两步ELISA的研究一致。发现抗JCV抗体阳性与年龄，性别，区域和免疫抑制剂治疗之间存在显着关联，而血清阳性率与种族，MS类型，MS持续时间或MS治疗次数或持续时间无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号